[go: up one dir, main page]

PE20080659A1 - Benzotriazoles como moduladores de quinasas - Google Patents

Benzotriazoles como moduladores de quinasas

Info

Publication number
PE20080659A1
PE20080659A1 PE2007001197A PE2007001197A PE20080659A1 PE 20080659 A1 PE20080659 A1 PE 20080659A1 PE 2007001197 A PE2007001197 A PE 2007001197A PE 2007001197 A PE2007001197 A PE 2007001197A PE 20080659 A1 PE20080659 A1 PE 20080659A1
Authority
PE
Peru
Prior art keywords
alkyl
benzotriazol
halogen
benzotriazoles
compounds
Prior art date
Application number
PE2007001197A
Other languages
English (en)
Inventor
David Michael Goldstein
Leyi Gong
Christophe Michoud
Wylie Solang Palmer
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20080659A1 publication Critical patent/PE20080659A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE BENZOTRIAZOLES DE FORMULA (I) DONDE R ES ALQUILO(C1-C6), HIDROXIALQUILO(C1-C6), UN COMPUESTO DE FORMULA (i), ENTRE OTROS, DONDE Ra ES H, ALQUILO(C1-C6), OH O HIDROXIALQUILO(C1-C6); Rb ES H, ALQUILO(C1-C6), HALOGENO, NITRO O HALO-ALQUILO(C1-C6); p ES DE 1 A 4; R1 ES H, HALOGENO, ALQUILO(C1-C12) O NH2; R3 ES HALOGENO, NO2, ALQUILO(C1-C6), CN, CF3, ENTRE OTROS; R2 ES H O ALQUILO(C1-C6); m ES DE 0 A 2. SON COMPUESTOS PREFERIDOS: TRANS-4-(4-BENZOTRIAZOL-1-IL-PIRIMIDIN-2-ILAMINO)-CICLOHEXANOL, 4-(4-BENZOTRIAZOL-1-IL-PIRIMIDIN-2-ILAMINO)-1-METIL-CICLOHEXANOL, ETILAMIDA DEL ACIDO TRANS-4-(4-BENZOTRIAZOL-1-IL-5-CLORO-PIRIMIDIN-2-ILAMINO)-CICLOHEXANOCARBOXILICO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LAS QUNASAS C-JUN-N-TERMINALES (JNK) Y LAS QUINASAS DEPENDIENTES DE CICLINA (CDK) SIENDO UTILES EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, ASMA, DIABETES DE TIPO II, LA ENFERMEDAD DE ALZHEIMER, LA ENFERMEDAD DE PARKINSON
PE2007001197A 2006-09-08 2007-09-06 Benzotriazoles como moduladores de quinasas PE20080659A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84309006P 2006-09-08 2006-09-08

Publications (1)

Publication Number Publication Date
PE20080659A1 true PE20080659A1 (es) 2008-05-17

Family

ID=38893293

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001197A PE20080659A1 (es) 2006-09-08 2007-09-06 Benzotriazoles como moduladores de quinasas

Country Status (17)

Country Link
US (1) US8962622B2 (es)
EP (1) EP2066319B1 (es)
JP (1) JP5325783B2 (es)
KR (1) KR101177729B1 (es)
CN (1) CN101511359B (es)
AR (1) AR062666A1 (es)
AT (1) ATE543498T1 (es)
AU (1) AU2007293917B2 (es)
BR (1) BRPI0717035B8 (es)
CA (1) CA2662998C (es)
CL (1) CL2007002572A1 (es)
ES (1) ES2378577T3 (es)
IL (1) IL197015A (es)
MX (1) MX2009002229A (es)
PE (1) PE20080659A1 (es)
TW (1) TW200819440A (es)
WO (1) WO2008028860A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
BRPI0720003A2 (pt) 2006-12-08 2018-09-18 Hoffmann La Roche pirimidinas substituídas e seu uso como moduladores de jnk
CA2909988A1 (en) * 2007-10-23 2009-04-30 F. Hoffmann-La Roche Ag Kinase inhibitors
ES2392788T3 (es) * 2008-05-16 2012-12-13 F. Hoffmann-La Roche Ag Inhibidores de las JNK
WO2009143865A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
US8569306B2 (en) 2009-02-24 2013-10-29 Hoffmann-La Roche, Inc. JNK modulators
KR101506318B1 (ko) 2009-08-10 2015-03-26 에프. 호프만-라 로슈 아게 Ｊｎｋ 억제제
CA2799328C (en) * 2010-06-04 2018-02-20 Humberto Bartolome Arzeno 2 -amino- pyrimidine derivatives useful as inhibitors of jnk
CA2799817A1 (en) * 2010-06-04 2011-12-08 Leyi Gong Inhibitors of jnk
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
AU2010362444B2 (en) 2010-10-14 2015-08-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
US8877694B2 (en) * 2011-02-09 2014-11-04 The Lubrizol Corporation Asphaltene dispersant containing lubricating compositions
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
EP3417850A1 (en) * 2013-02-25 2018-12-26 Aurigene Discovery Technologies Limited Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
AU2014301631A1 (en) 2013-06-26 2015-08-27 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
ES2702951T3 (es) 2014-04-04 2019-03-06 Syros Pharmaceuticals Inc Inhibidores de quinasas dependientes de ciclina 7 (cdk7)
US9908896B2 (en) 2014-06-16 2018-03-06 Allinky Biopharma P38 and JNK MAPK inhibitors for the treatment and prophylaxis of degenerative diseases of the nervous system
WO2017204626A1 (en) 2016-05-24 2017-11-30 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Combination therapy - combined map2k4/map3k1 and mek/erk inhibition
WO2018029336A1 (en) 2016-08-12 2018-02-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
CN108117523B (zh) * 2016-11-29 2021-05-07 上海医药工业研究院 卤代尿嘧啶类化合物的制备方法
SMT202100553T1 (it) 2017-04-24 2021-11-12 Aurigene Discovery Tech Ltd Metodi d'uso per derivati benzotriazolici trisostituiti come inibitori di diidroorotato ossigenasi
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
KR102861339B1 (ko) 2018-02-20 2025-09-19 르 라보레또레 쎄르비에르 삼치환 벤조트리아졸 유도체의 사용 방법
CN116323569A (zh) * 2020-09-15 2023-06-23 田边三菱制药株式会社 三嗪化合物的盐、其晶型及制造方法
CN114456126A (zh) * 2022-02-26 2022-05-10 郑州萃智医药科技有限公司 一种化合物的合成方法
CN115677595B (zh) * 2022-10-26 2024-06-14 江苏睿实生物科技有限公司 一种2,4,5-三氯嘧啶的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1206265B1 (en) * 1999-06-30 2003-11-12 Merck & Co., Inc. Src kinase inhibitor compounds
CA2376957A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
CA2491895C (en) 2002-07-09 2011-01-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
TW200610762A (en) 2004-06-10 2006-04-01 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US20060281764A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
RU2008141761A (ru) 2006-03-22 2010-04-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ

Also Published As

Publication number Publication date
JP2010502668A (ja) 2010-01-28
CN101511359A (zh) 2009-08-19
KR101177729B1 (ko) 2012-09-07
AU2007293917A1 (en) 2008-03-13
IL197015A0 (en) 2009-11-18
IL197015A (en) 2013-12-31
CN101511359B (zh) 2012-09-05
BRPI0717035A2 (pt) 2014-11-25
JP5325783B2 (ja) 2013-10-23
BRPI0717035B1 (pt) 2021-05-04
CA2662998C (en) 2015-10-06
AU2007293917B2 (en) 2013-01-31
WO2008028860A1 (en) 2008-03-13
EP2066319A1 (en) 2009-06-10
MX2009002229A (es) 2009-03-16
KR20090040908A (ko) 2009-04-27
AR062666A1 (es) 2008-11-26
US20080103142A1 (en) 2008-05-01
CL2007002572A1 (es) 2008-04-18
ATE543498T1 (de) 2012-02-15
CA2662998A1 (en) 2008-03-13
EP2066319B1 (en) 2012-02-01
TW200819440A (en) 2008-05-01
BRPI0717035B8 (pt) 2021-05-25
US8962622B2 (en) 2015-02-24
ES2378577T3 (es) 2012-04-16

Similar Documents

Publication Publication Date Title
PE20080659A1 (es) Benzotriazoles como moduladores de quinasas
PE20121352A1 (es) Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20070593A1 (es) Compuestos pirrolopirimidina como inhibidores de syk
BRPI0514371A (pt) 2, 4 di (aminofenil) pirimidina como inibidores de plk
PE20110285A1 (es) Derivados de sulfonamidofenil propionamida como ligandos del receptor vaniloide del subtipo 1
PE20071227A1 (es) Compuestos derivados de indazol como moduladores del receptor de glucocorticoides
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20071156A1 (es) COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA)
PE20090815A1 (es) Compuesto de amida
PE20071095A1 (es) Derivados policiclicos de indazol como inhibidores de erk
PE20130602A1 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
NO20063469L (no) Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister
PE20070121A1 (es) 2,4-diamino-pirimidinas como inhibidores de aurora
NO20063468L (no) Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister
PE20140966A1 (es) Quinazolincarboxamida azetidinas
PE20130382A1 (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
PE20141973A1 (es) Compuestos de heterociclilo como inhibidores de mek
PE20080074A1 (es) Derivados de amida como agentes inhibidores de la quinasa c-fms
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20081507A1 (es) Derivados de pirimidina como moduladores de jnk
PE20070362A1 (es) COMPUESTOS DERIVADOS DE INDAZOL-4-IL-2,4-PIRIMIDINDIAMINA COMO INHIBIDORES DE TIROSINA QUINASA (QUINASA Syk)
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
PE20181492A1 (es) Compuestos sustituidos de 4-fenilpiridina como agonistas de tgr5 no sistemicos

Legal Events

Date Code Title Description
FG Grant, registration